Thermodynamics of nucleotide and non-ATP-competitive inhibitor binding to MEK1 by circular dichroism and isothermal titration calorimetry

Biochemistry

Volumn 46, Issue 5, 2007, Pages 1358-1367

  Smith, Catherine K ^a   Windsor, William T ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING ENERGY; CALORIMETRY; ENZYME INHIBITION; GROWTH KINETICS; ISOTHERMS; THERMODYNAMIC PROPERTIES;

DOMAIN FUNCTIONS; ENZYMATIC ACTIVITY; ISOTHERMAL TITRATION CALORIMETRY; THERMODYNAMIC PARAMETERS;

NUCLEIC ACIDS;

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; ADENOSINE DIPHOSPHATE; ADENOSINE PHOSPHATE; ADENOSINE TRIPHOSPHATE; CYTOKINE; GROWTH FACTOR; MAGNESIUM; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; NUCLEOTIDE;

ALLOSTERISM; ARTICLE; BINDING AFFINITY; CIRCULAR DICHROISM; DRUG PROTEIN BINDING; ENTHALPY; ENZYME ACTIVITY; ENZYME INHIBITOR INTERACTION; ISOTHERMAL TITRATION CALORIMETRY; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FOLDING; SIGNAL TRANSDUCTION; TEMPERATURE DEPENDENCE; THERMODYNAMICS;

ADENOSINE DIPHOSPHATE; ADENYLYL IMIDODIPHOSPHATE; ALLOSTERIC REGULATION; BINDING, COMPETITIVE; CALORIMETRY; CIRCULAR DICHROISM; HUMANS; LIGANDS; MAP KINASE KINASE 1; NUCLEOTIDES; PHOSPHORYLATION; PROTEIN BINDING; THERMODYNAMICS;

EID: 33846834003     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi061893w     Document Type: Article

References (37)

1. English, J., and Cobb, M. (2002) Pharmacological inhibitors of MAPK pathways, Trends Pharmacol. Sci. 23, 40-45.
2. Pearson, G., Robinson, F., Beers-Gibson, T., Xu, B., Karandikar, M., Berman, K., and Cobb, M. H. (2001) Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions, Endocr. Rev. 22, 153-183.
3. Sears, R. C., and Kevins, J. R. (2002) Signaling networks that link cell proliferation and cell fate, J. Biol. Chem. 277, 11617-11620.
4. Lewis, T. S., Shapiro, P. S., and Ahn, N. G. (1998) Signal transduction through MAP kinase cascades, Adv. Cancer Res. 74, 49-139.
5. Payne, D. M., Rossomando, A. J., Martino, P., Erickson, A. K., Her, J. H., Shabanowitz, J., Hunt, D. F., Weber, M. J., and Sturgill, T. W. (1991) Identification of the regulatory phosphorylation sites in pp42/mitogen-activated protein kinase (MAP kinase), EMBO J. 10, 885-892.
6. Seger, R., Ahn, N. G., Posada, J., Munar, E. S., Jensen, A. M., Cooper, J. A., Cobb, M. H., and Krebs, E. G. (1992) Purification and characterization of mitogen-activated protein kinase activator(s) from epidermal growth factor-stimulated A431 cells, J. Biol. Chem. 267, 14373-14381.
7. Robbins, D. J., Zhen, E., Owaki, H., Vanderbilt, C. A., Ebert, D., Geppert, T. D., and Cobb, M. H. (1993) Regulation and properties of extracellular signal-regulated protein kinases 1 and 2 in vitro, J. Biol. Chem. 268, 5097-5106.
8. Resing, K. A., and Ahn, N. G. (1998) Deuterium exchange mass spectrometry as a probe of protein kinase activation. Analysis of wild-type and constitutively active mutants of MAP kinase kinase-1, Biochemistry 37, 463-475.
9. Alessi, D. R., Saito, Y., Campbell, D. G., Cohen, P., Sithanandam, G., Rapp, U., Ashworth, A., Marshall, C. J., and Cowley, S. (1994) Identification of the sites in MAP kinase kinase-1 phosphorylated by p74raf-1, EMBO J. 13, 1610-1619.
10. Zheng, C.-F., and Guan, K.-L. (1994) Activation of MEK family kinases requires phosphorylation of two conserved Ser/Thr residues, EMBO J. 13, 1123-1131.
11. Brunet, A., Pages, G., and Pouyssegur, J. (1994) Constitutively active mutants of MAP kinase kinase (MEK1) induce growth factor-relaxation and oncogenicity when expressed in fibroblasts, Oncogene 9, 3379-3387.
12. Cowley, S., Paterson, H., Kemp, P., and Marshall, C. J. (1994) Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells, Cell 77, 841-852.
13. Mansour, S. J., Matten, W. T., Hermann, A. S., Candia, J. M., Rong, S., Fukasawa, K., Vande Woude, G. F., and Ahn, N. G. (1994) Transformation of mammalian cells by constitutively active MAP kinase kinase, Science 265, 966-970.
14. Huang, W., Kessler, D. S., and Erikson, R. L. (1995) Biochemical and biological analysis of Mek1 phosphorylation site mutants, Mol. Biol. Cell 6, 237-245.
15. Mansour, S. J., Candia, J. M., Matsuura, J. E., Manning, M. C., and Ahn, N. G. (1996) Interdependent domains controlling the enzymatic activity of mitogen-activated protein kinase kinase 1, Biochemistry 3, 15529-15536.
16. Herrera, R., and Sebolt-Leopold, J. S. (2002) Unraveling the complexities of the Raf/MAP kinase pathway for pharmacological intervention, Trends Mol. Med. 8, S27-S31.
17. Alessi, D. R., Cuenda, A., Cohen, P., Dudley, D. T., and Saltiel, A. R. (1995) PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo, J. Biol. Chem. 270, 27489-27494.
18. Dudley, D. T., Pang, L., Decker, S. J., Bridges, A. J., and Saltiel, A. R. (1995) A synthetic inhibitor of the mitogen-activated protein kinase cascade, Proc. Natl. Acad. Sci. U.S.A. 92, 7686-7689.
19. Favata, M. F., Horiuchi, K. Y., Manos, E. J., Daulerio, A. J., Stradley, D. A., Feeser, W. S., Van-Dyk, D. E., Pitts, W. J., Earl, R. A., Hobbs, F., Copeland, R. A., Magolda, R. L., Scherle, P. A., and Trzaskos, J. M. (1998) Identification of a novel inhibitor of mitogen-activated protein kinase kinase, J. Biol. Chem. 273, 18623-18632.
20. Delaney, A. M., Printen, J. A., Huifen, C., Fauman, E. B., and Dudley, D. T. (2002) Identification of a novel mitogen-activated protein kinase kinase activation domain recognized by the inhibitor PD184352, Mol. Cell. Biol. 22, 7593-7602.
21. Sebolt-Leopold, J. S., Dudley, D. T., Herrera, R., Van Becelaere, K., Wiland, A., Gowan, R. C., Tecle, H., Barrett, S. D., Bridges, A., Przybranowski, S., Leopold, W. R., and Saltiel, A. R. (1999) Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo, Nat. Med. 5, 810-816.
22. Ohren, J. F., Chen, H., Pavlovsky, A., Whitehead, C., Zhang, E., Kuffa, P., Yan, C., McConnell, P., Spessard, C., Banotai, C., Mueller, W. T., Delaney, A., Omer, C., Sebolt-Leopold, J., Dudley, D. T., Leung, I. K., Flamme, C., Warmus, J., Kaufman, M., Barrett, S., Tecle, H., and Hasemann, C. A. (2004) Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition, Nature Struct. Mol. Biol. 11, 1192-1197.
23. Davies, S. P., Reddy, H., Caivano, M., and Cohen, P. (2000) Specificity and mechanism of action of some commonly used protein kinase inhibitors, Biochem. J. 351, 95-105.
24. Solit, D. B., Garraway, L. A., Pratilas, C. A., Sawai, A., Getz, G., Basso, A., Ye, Q., Lobo, J. M., She, Y., Osman, I., Golub, T. R., Sebolt-Leopold, J., Sellers, W. R., and Rosen, N. (2006) BRAF mutation predicts sensitivity to MEK inhibition, Nature 439, 358-362.
25. Khokhlatchev, A. V., Canagarajah, B., Wilsbacher, J., Robinson, M., Atkinson, M., Goldsmith, E., and Cobb, M. H. (1998) Phosphorylation of the MAP kinase ERK2 promotes its homodimerization and nuclear translocation, Cell 93, 605-615.
26. Smith, C. K., Carr, D., Mayhood, T. W., Jin, W., Gray, K., and Windsor, W. T. (2006) Expression and purification of phosphorylated and non-phosphorylated human MEK1, Protein Expr. Purif., in press.
27. Sebolt-Leopold, J. S., and Herrera, R. (2004) Targeting the mitogen-activated protein kinase cascade to treat cancer, Nat. Rev. Cancer 12, 937-947.
28. Waldron, T. T., and Murphy, K. P. (2003) Stabilization of proteins by ligand binding: application to drug screening and determination of unfolding energetics, Biochemistry 42, 5058-5064.
29. Pantoliano, M. W., Petrella, E. C., Kwasnoski, J. D., Lobanov, V. S., Myslik, J., Graf, E., Carver, T., Asel, E., Springer, B. A., Lane, P., and Salemme, F. R. (2001) High-density miniaturization thermal shift assays as a general strategy for drug discovery, J. Biomol. Screening 6, 429-440.
30. Matulis, D., Kranz, J. K., Salemme, F. R., and Todd, M. J. (2005) Thermodynamic stability of carbonic anhydrase: measurements of binding affinity and stoichiometry using ThermoFluor, Biochemistry 44, 5258-5266.
31. Brandts, J. F., and Lin, L. N. (1990) Study of strong to ultralight protein interactions using differential scanning calorimetry, Biochemistry 29, 6927-6940.
32. Mayhood, T. W., and Windsor, W. T. (2005) Ligand binding affinity determined by temperature-dependent circular dichroism: cyclin-dependent kinase 2 inhibitors, Anal. Biochem. 345, 187-197.
33. Murphy, K. P., Xie, D., Garcia, K. C., Amzel, L. M., and Friere, E. (1993) Structural energetics of peptide recognition: angiotensin II/antibody binding, Proteins 15, 113-120.
34. Gomez, J., and Friere, E. (1995) Thermodynamic mapping of the inhibitor site of the aspartic protease endothiapepsin, J. Mol. Biol. 252, 337-350.
35. Kohno, M., and Pouyssegur, J. (2006) Targeting the ERK signaling pathway in cancer therapy, Anal. Med. 38, 200-211.
36. Bakare, O., Ashendel, C. L., Peng, H., Zalkow, L. H., and Burgess, E. M. (2003) Synthesis and MEK1 inhibitory activities of imido-substituted 2-chloro-1,4-naphthoquinones, Bioorg. Med. Chem. 11, 3165-3170.
37. Wityak, J., Hobbs, F. W., Gardner, D. S., Santella, J. B. r., Petraitis, J. J., Sun, J. H., Favata, M. F., Daulerio, A. J., Horiuchi, K. Y., Copeland, R. A., Scherle, P. A., Jaffe, B. D., Trzaskos, J. M., Magolda, R. L., Trainor, G. L., and Duncia, J. V. (2004) Beyond U0126. Dianion chemistry leading to the rapid synthesis of a series of potent MEK inhibitors, Bioorg. Med. Chem. Lett. 14, 1483-1486.